TP53 and B-cell non-Hodgkin lymphoma: To determine if a regulatory feedback mechanism exists between DYRK1A and MYC, we analyzed DYRK1A expression levels at different stages during B cell development including transgenic mouse model systems with overexpression of Bcl6 or Myc/Bcl6 or deletion of Lig4/tp53, three distinct models of B cell lymphoma [40].